A validated integrated clinical and molecular glioblastoma long-term survival-predictive nomogram.

ABSTRACT:

Background

Glioblastoma (GBM) is the most common primary malignant brain tumor in adulthood. Despite multimodality treatments, including maximal safe resection followed by irradiation and chemotherapy, the median overall survival times range from 14 to 16 months. However, a small subset of GBM patients live beyond 5 years and are thus considered long-term survivors.

Methods

A retrospective analysis of the clinical, radiographic, and molecular features of patients with newly diagnosed primary GBM who underwent treatment at The University of Texas MD Anderson Cancer Center was conducted. Eighty patients had sufficient quantity and quality of tissue available for next-generation sequencing and immunohistochemical analysis. Factors associated with survival time were identified u

SUBMITTER: Ferguson SD 

PROVIDER: S-EPMC7780842 | biostudies-literature | 2021 Jan-Dec

REPOSITORIES: biostudies-literature